Oramed Pharmaceuticals (ORMP) Equity Average (2011 - 2026)

Oramed Pharmaceuticals has reported Equity Average for 16 years, with the latest figure at $219.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 53.56% year-over-year to $219.0 million; the trailing twelve-month figure through Mar 2026 stood at $219.0 million (up 53.56% YoY), and the FY2025 full-year result was $172.5 million, up 11.96% from the prior year.
• Equity Average for Q1 2026 stood at $219.0 million, up from $201.0 million in the prior quarter.
• The five-year high for Equity Average was $219.0 million in Q1 2026, with the low at $142.6 million in Q1 2025.
• Historically, Equity Average has averaged $163.2 million across 5 years, with a median of $155.6 million in 2023.
• Annual changes were most pronounced in 2025 — Equity Average decreased 14.16% — and 2026, when it surged 53.56%.
• Oramed Pharmaceuticals' Equity Average stood at $152.2 million in 2022, then grew by 2.24% to $155.6 million in 2023, then fell by 3.3% to $150.4 million in 2024, then surged by 33.64% to $201.0 million in 2025, then grew by 8.94% to $219.0 million in 2026.
• The last three Equity Average figures came in at $219.0 million (Q1 2026), $201.0 million (Q4 2025), and $178.0 million (Q3 2025), per Business Quant data.